Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

NCT01840410 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization (CNV)

Interventions

DRUG: Ranibizumab
OTHER: Sham control

Sponsor

Novartis Pharmaceuticals